Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
정재욱, 최석환, 김범수, 김태환, 유은상, 김천일, 이경섭, 권태균,
소속 상세정보
정재욱 ( Chung Jae-Wook )
Kyungpook National University School of Medicine Department of Urology
최석환 ( Choi Seock-Hwan )
Kyungpook National University School of Medicine Department of Urology
김범수 ( Kim Bum-Soo )
Kyungpook National University School of Medicine Department of Urology
김태환 ( Kim Tae-Hwan )
Kyungpook National University School of Medicine Department of Urology
유은상 ( Yoo Eun-Sang )
Kyungpook National University School of Medicine Department of Urology
김천일 ( Kim Chun-Il )
Keimyung University School of Medicine Department of Urology
이경섭 ( Lee Kyung-Seop )
Dongguk University School of Medicine Department of Urology
권태균 ( Kwon Tae-Gyun )
Kyungpook National University School of Medicine Department of Urology
KMID : 0358320110520070479
Abstract
Purpose: To evaluate the efficacy and tolerability of tamsulosin 0.4 mg once daily in Korean patients with symptomatic benign prostatic hyperplasia (BPH) and investigate whether tamsulosin 0.4 mg can improve symptoms in patients with refractory lower urinary tract symptoms (LUTS) who were previously receiving tamsulosin 0.2 mg once daily.
Materials and Methods: A total of 116 patients from 3 urology centers participated. All study subjects entered a nonblind phase consisting of 8 weeks of tamsulosin 0.2 mg monotherapy followed by an additional 8 weeks of tamsulosin 0.2 mg (0.2 mg group) or 8 weeks of tamsulosin 0.4 mg (0.4 mg group). At week 8, we chose the 0.4 mg group on the basis of International Prostate Symptom Score (IPSS), quality of life (QoL), maximal urinary flow rate (Qmax), and adverse effects. At week 16, we compared the efficacy and tolerability of tamsulosin between the 0.2 and 0.4 mg groups.
Results: A total of 26 patients (22.4%) were escalated to tamsulosin 0.4 mg at week 8. There were significant differences in IPSS, QoL, and Qmax at week 8 in both groups. There were significant differences in improvement in IPSS, QoL, Qmax, and postvoid residual urine volume from baseline to week 16 in both groups. There were no significant differences in efficacy or tolerability between the groups at week 16.
Conclusions: Our trial demonstrated that tamsulosin 0.4 mg has favorable efficacy and tolerability in Korean patients with symptomatic BPH refractory to tamsulosin 0.2 mg. No patients experienced any serious adverse effects when we escalated the dose of tamsulosin to 0.4 mg.
키워드
Prostatic hyperplasia; Tamsulosin
원문 및 링크아웃 정보
등재저널 정보